Jeremy Dennison

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Andrew J. Pollard, Odile Launay, Jean‐Daniel Lelièvre et al. · The Lancet Infectious Diseases · 2020 · 170 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials

Florian Wagenlehner, Caroline Perry, Thomas M. Hooton et al. · The Lancet · 2024 · 82 citations

Pharmacy, Infectious Diseases, Pharmacology +11

ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study

Dominic Beale, Jeremy Dennison, Malcolm Boyce et al. · British Journal of Clinical Pharmacology · 2021 · 39 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +4

Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects

Jean‐Yves Gillon, Jeremy Dennison, Frans van den Berg et al. · British Journal of Clinical Pharmacology · 2021 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10

A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study

Étienne Dumont, Amanda J. Oliver, Christos V. Ioannou et al. · Antimicrobial Agents and Chemotherapy · 2020 · 25 citations · Full text

Pharmacy, Infectious Diseases, Pharmaceutics +17